Categories AlphaGraphs, Earnings, Health Care
VRTX Earnings: A snapshot of Vertex Pharmaceuticals’ Q1 2023 results
Healthcare firm Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) on Monday reported a decline in adjusted earnings for the first quarter, despite an increase in revenues.
Total revenues increased to $2.37 billion in the first quarter from $2.10 billion in the corresponding period of 2022. For the full fiscal year, the management expects product revenues to be between $9.55 billion and $9.70 billion.
Meanwhile, adjusted earnings dropped to $3.05 per share in the March quarter from $3.52 per share in the prior-year period. Unadjusted profit was $699.8 million or $2.69 per share, compared to $762.1 million or $2.96 per share last year.
Prior Performance
Looking for more insights on the earnings results? Click here to access the full transcripts of the latest earnings conference calls!
Most Popular
CL Earnings: Key quarterly highlights from Colgate-Palmolive’s Q2 2024 financial results
Colgate-Palmolive Company (NYSE: CL) reported its second quarter 2024 earnings results today. Net sales increased 4.9% year-over-year to $5 billion. Organic sales increased 9%. Net income attributable to Colgate-Palmolive Company was $731
Key takeaways from Visa’s Q3 2024 earnings report
Credit card behemoth Visa, Inc. (NYSE: V) this week reported mixed results for the June quarter, with earnings matching expectations and sales slightly missing the view. Both numbers grew in
Southwest Airlines (LUV): A look at the airline’s performance in Q2 2024
Shares of Southwest Airlines Co. (NYSE: LUV) were up over 6% on Thursday after the company beat earnings estimates for the second quarter of 2024. The stock has gained 4%
